Six-month effective treatment of corneal graft rejection-Reference-Cited by-同舟云学术

Six-month effective treatment of corneal graft rejection

Published:2023-03-24 Issue:12 Volume:9 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Meng Tuo¹^ORCID,Zheng Jinhua¹²^ORCID,Chen Min³⁴⁵^ORCID,Zhao Yang¹⁶^ORCID,Sudarjat Hadi¹^ORCID,M.R. Aji Alex¹,Kulkarni Vineet¹,Oh Yumin⁵,Xia Shiyu⁵^ORCID,Ding Zheng⁵^ORCID,Han Hyounkoo⁴⁵,Anders Nicole⁷,Rudek Michelle A.⁷^ORCID,Chow Woon⁸^ORCID,Stark Walter⁴⁵,Ensign Laura M.⁴⁵^ORCID,Hanes Justin⁴⁵^ORCID,Xu Qingguo¹⁸⁹^ORCID

Affiliation:

1. Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA.

2. Department of Ophthalmology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550004, China.

3. Eye Institute of Shandong First Medical University, Qingdao Eye Hospital of Shandong First Medical University, Qingdao, Shandong 266073, China.

4. Department of Ophthalmology, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, 400 North Broadway, Baltimore, MD 21231, USA.

5. Center for Nanomedicine, The Johns Hopkins University School of Medicine, 400 North Broadway, Baltimore, MD 21231, USA.

6. Department of Ophthalmology, Second Xiangya Hospital of Central South University, Changsha, Hunan, China.

7. Department of Medicine, The Johns Hopkins University, Baltimore, MD 21231, USA.

8. Department of Ophthalmology, Virginia Commonwealth University, Richmond, VA 23298, USA.

9. Center for Pharmaceutical Engineering and Institute for Structural Biology, Drug Discovery and Development (ISB3D), Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.

Abstract

Topical corticosteroid eye drop is the mainstay for preventing and treating corneal graft rejection. While the frequent topical corticosteroid use is associated with risk of intraocular pressure (IOP) elevation and poor patient compliance that leads to graft failure and the requirement for a repeated, high-risk corneal transplantation. Here, we developed dexamethasone sodium phosphate (DSP)–loaded dicarboxyl-terminated poly(lactic acid) nanoparticle (PLA DSP-NP) formulations with relatively high drug loading (8 to 10 weight %) and 6 months of sustained intraocular DSP delivery in rats with a single dosing. PLA DSP-NP successfully reversed early signs of corneal rejection, leading to rat corneal graft survival for at least 6 months. Efficacious PLA DSP-NP doses did not affect IOP and showed no signs of ocular toxicity in rats for up to 6 months. Subconjunctival injection of DSP-NP is a promising approach for safely preventing and treating corneal graft rejection with the potential for improved patient adherence.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Link

https://www.science.org/doi/pdf/10.1126/sciadv.adf4608

Reference57 articles.

1. World Health Organization Blindness and vision impairment (2020);www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment.

2. Corneal transplantation

3. Chitosan and Its Derivatives for Application in Mucoadhesive Drug Delivery Systems

4. Global Survey of Corneal Transplantation and Eye Banking

5. Advances in corneal graft rejection

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long‐Acting Ocular Injectables: Are We Looking In The Right Direction?;Advanced Science;2023-11-28

2. Yolo-Et: A Machine Learning Model for Detecting, Localising and Classifying Anthropogenic Contaminants and Extraterrestrial Microparticles Optimised for Mobile Processing Systems;2023